A dramatic fetal outcome following transplacental transfer of dasatinib.
Anticancer Drugs
; 23(7): 754-7, 2012 Aug.
Article
en En
| MEDLINE
| ID: mdl-22421368
ABSTRACT
Chronic myeloid leukemia is a chronic myeloproliferative disorder of hematopoietic stem cells that occurs in 10% of cases in women of childbearing age. Treatment is mainly based on tyrosine kinase inhibitors such as imatinib, dasatinib, or nilotinib. However, the maternal and embryofetal safety of these drugs in pregnant women is poorly documented. Here, we report the case of a 23-year-old woman diagnosed with a chronic myeloid leukemia. She was treated with dasatinib while she was diagnosed as being pregnant at 7 weeks of gestation. Obstetric monitoring showed fetal hydrops associated with severe fetal bicytopenia, leading to termination of pregnancy at 16 weeks of gestation. Dasatinib concentrations were 4 ng/ml in maternal plasma (usual concentration), 3 ng/ml in fetal plasma, and 2 ng/ml in amniotic fluid. Fetal karyotype was normal. To our knowledge, this is the first report clearly quantifying the amount of transplacental transfer of dasatinib. Moreover, fetal hematological toxicity (leukopenia and thrombocytopenia), edema, ascites, and pleural effusions described in this case report are well-known side effects of dasatinib in adults. Hence, this case highlights the imputability of dasatinib in this adverse outcome, and clearly questions its safety during pregnancy.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Complicaciones Neoplásicas del Embarazo
/
Pirimidinas
/
Tiazoles
/
Leucemia Mielógena Crónica BCR-ABL Positiva
/
Inhibidores de Proteínas Quinasas
/
Feto
/
Intercambio Materno-Fetal
Tipo de estudio:
Etiology_studies
Límite:
Adult
/
Female
/
Humans
/
Pregnancy
Idioma:
En
Revista:
Anticancer Drugs
Asunto de la revista:
ANTINEOPLASICOS
Año:
2012
Tipo del documento:
Article
País de afiliación:
Francia